NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital announces significant participation in upsized $207.5 million Series C financing in Aviceda Therapeutics to advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials
Investment will support the ongoing Phase 2b/3 and planned pivotal Phase 3 clinical trial for AVD-104 in geographic atrophy secondary to age-related macular degeneration (AMD); Aviceda’s ongoing Phase 2b/3 trial evaluating AVD-104 is fully enrolled, with 12-month...
Download our White Paper
We are pleased to share with you our White Paper, which offers a deep dive into the evolving biopharma landscape and highlights the key trends shaping its future.
Find all our press releases
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for Claudin-1 in cancer & fibrosis
Funds will support the Phase I/II clinical development of Alentis’ two first-in-class...
Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders
Noema Pharma's clinical-stage assets and diversified pipeline hold significant potential in...
Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing
The Series C extension round will accelerate clinical development, manufacturing scale-up and...
Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics
Deal validates Jeito’s unique investment model of selecting high-quality assets developed by...
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer
Jeito Capital co-leads oversubscribed EUR 50 million Series C financing with Brandon Capital...
Jeito Capital becomes significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases
Jeito Capital participates in $120 million financing alongside ARCH Venture Partners and Monograph...
Face to face
Meet Jeito
16-17
December
All day long
Conference of Paris 2024
Jeito will be present at the Conference of Paris 2024, for its 8th edition around the theme “Confronting the Unknown”, encouraging leaders to share their knowledge and understanding of global economic, social and environmental issues as a way to collaborate and collectively overcome these challenges.
13-16
January
All day long
JPM Healthcare Conference 2025
Jeito will be present at the 43rd JPM Healthcare Conference 2025, renowned as the largest and most influential healthcare investment symposium, attracting global industry leaders, Biotech companies, and members of the investment community, in San Francisco.
28-30
January
All day long
IPEM Cannes 2025
Jeito will be present at the 11th edition of IPEM Cannes – Wealth 2025, gathering Private Capital key decision-makers and incubating this year “IPEM Wealth”, a brand-new format designed to support the democratization of Private Markets, in Cannes.